Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACY-241 with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02400242Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- May 2015
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of citarinostat in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Maximum tolerated dose of ACY-241 as monotherapy and Maximum tolerated dose of ACY-241 in combination with pomalidomide and low dose dexamethasone. Started May 2015; status: terminated.
02
Drugs
citarinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02400242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400242.